Navigation Links
Midwest Research Institute Selected to Help Companies Advance the Development of Influenza Vaccines
Date:5/4/2009

KANSAS CITY, Mo., May 4 /PRNewswire-USNewswire/ -- Recognized internationally for its expertise in virology and toxicology, Midwest Research Institute (MRI) has been selected by PATH to support its vaccine partner companies in advancing the development of new, safe, and effective influenza vaccines. The goal of the PATH effort is to produce vaccines more quickly, economically, and in large quantities to counter a global influenza pandemic.

MRI, headquartered in Kansas City, is one of the nation's leading independent scientific organizations conducting contract research for government, industry and academia since 1944.

PATH, an international, nonprofit organization, creates sustainable, culturally relevant solutions that enable communities worldwide to break longstanding cycles of poor health. In 2008, PATH launched a vaccine research program to accelerate influenza vaccine development through partnerships with public- and private-sector organizations.

Through the agreement, PATH partner companies will contract with MRI to perform assays and preclinical studies using influenza vaccine candidates. These studies will include in-vivo and in-vitro experiments, animal safety studies, and chemistry support activities. PATH strives to consolidate and standardize the preclinical animal testing at a single source, MRI, to improve consistency of study performance and reliability and reproducibility of associated data for their partnering companies.

"The opportunity to support PATH in their mission to improve world health is an exceptional achievement for MRI," said Thomas Sack, Ph.D., MRI Regional Vice President of Midwest Operations. "Our selection by PATH is recognition of MRI's excellence in biological and health sciences and our outstanding vaccine development and influenza virus testing programs."

About Midwest Research Institute

<
'/>"/>
SOURCE Midwest Research Institute
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Ohio Health Care Association/Ohio Centers for Assisted Living Host Midwests Largest Long-Term Care Convention in Columbus
2. Newt Gingrich to Address Chicago Employers at Midwest Business Group on Healths 29th Annual Conference
3. Houlihan Smith to Host Illinois Venture Capital Association Luncheon Seminar on Midwest Healthcare Investing
4. No April Fooling: Higher Taxes On Tobacco Really Do Reduce Smoking, Says American Lung Association of Upper Midwest
5. Midwest and Northeast May Face Surgeon Shortage
6. American Lung Association of Upper Midwest Offers Tips on Dealing With Floodwaters
7. Midwestern and Southern States Receive Least Federal Funding for Disease Prevention
8. Adventist Midwest Health Engages Medium Blue Search Engine Marketing in Geographically-Targeted SEO Campaign
9. MassMutual Retirement Services Hires New TPA Relationship Manager for Midwest Region
10. The Midwest Center for Stress and Anxiety Re-launches Website for Stress, Anxiety, and Depression
11. Midwest Pulmonary and Critical Care Associates Will Join Aurora Medical Group
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Childrens Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 62578 1Childrens Hospitals and Clinics of Minnesota Receives National Recognition for Quality and Efficiency 62578 2Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 62575 1Settlement in AMA Lawsuit against UnitedHealth Gets Preliminary Approval from Federal Court 62575 2VIDEO from Medialink and the American Nurses Association 28ANA 29 3A American Nurses Association Urges All Americans to Take Part in Health Care Refo 62572 1VIDEO from Medialink and the American Nurses Association 28ANA 29 3A American Nurses Association Urges All Americans to Take Part in Health Care Refo 62572 2